224 results on '"Mozessohn, Lee"'
Search Results
2. Health care utilization and costs for frail vs nonfrail patients with diffuse large B-cell lymphoma
3. Fracture risk among patients with cancer compared to individuals without cancer: a population-based study
4. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML
5. Marital status, frailty, and survival in older adults with blood cancer
6. Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study
7. The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes
8. Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting.
9. Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
10. EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia
11. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE
12. The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study
13. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies
14. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies.
15. A Markov analysis of azacitidine and venetoclax versus induction chemotherapy for medically-fit patients with AML
16. Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study
17. P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA
18. Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes
19. EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia
20. Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review
21. Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis
22. The Impact of Drug Interactions on Outcomes in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia in Routine Clinical Care: A Population-Based Cohort Study
23. Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review
24. Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists
25. Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review
26. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: results of a pilot randomised trial RBC-ENHANCE and a combined analyses with REDDS
27. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
28. High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
29. Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers
30. Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study
31. The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study
32. Impact of Polypharmacy and Potentially Inappropriate Medications Among Older Adults With Blood Cancers
33. Factors Affecting Knowledge of Sexually Transmitted Infection Transmissibility in Healthcare Providers: Results From a National Survey
34. The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes
35. The Impact of Marginalization on Diffuse Large B-Cell Lymphoma Overall Survival: A Retrospective Cohort Study
36. Incidence of Mental Health Events and Its Association with Survival Among Patients with Diffuse Large B-Cell Lymphoma: A Population-Based Cohort Study
37. Impact of Polypharmacy and Potentially Inappropriate Medications Among Older Adults with Blood Cancers
38. Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies
39. Prognostic value of disease risk score versus gait speed in older adults with lymphoma
40. Shorter Diagnosis-to-Treatment Interval in Diffuse Large B-Cell Lymphoma is Associated With Inferior Overall Survival in a Large, Population-Based Registry
41. Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia
42. Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment
43. Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study
44. Frailty Is Associated with Increased One-Year Mortality in Patients with Newly Diagnosed Diffuse Large-B-Cell Lymphoma: A Population-Based Study
45. Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study
46. High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS
47. Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast–Count Acute Myeloid Leukemia
48. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada
49. Statin and cyclooxygenase‐2 inhibitors improve survival in newly diagnosed diffuse large B‐cell lymphoma: a large population‐based study of 4913 subjects
50. Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the ‘real-world’
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.